BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16418187)

  • 1. A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
    Cho KH; Song YB; Choi IS; Cho EH; Choi JW; Ahn YM; Roh YH; Nam SH; Kim BS
    Jpn J Clin Oncol; 2006 Jan; 36(1):50-4. PubMed ID: 16418187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
    Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
    J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
    Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
    Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
    Ohyanagi F; Taguchi F; Horai T; Kasahara K; Takeda Y; Shibata K; Shirosaki H; Nishio M
    Jpn J Clin Oncol; 2006 Sep; 36(9):547-51. PubMed ID: 16870693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
    Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
    Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
    Xiong JP; Zhang L; Zhong LX; Qiu F; Guo YL; Lian HY; Luo H
    Ai Zheng; 2006 Aug; 25(8):995-8. PubMed ID: 16965681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
    Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
    Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
    Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
    Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
    Mori K; Kobayashi H; Kamiyama Y; Kano Y; Kodama T
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):73-8. PubMed ID: 18941748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
    Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
    Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
    Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
    Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
    Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
    Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.